In addition, activating cyclin D gene mutations may enhance sensitivity to CDK4/6 inhibitors, while cyclin D deficiency is associated with CDK4/6 inhibitor resistance [75]. This evidence concerns the gene CDK4 and hyperinsulinemic hypoglycemia, familial, 4.